May 2023 - Pharmaceutical Market Europe

May 2023 - Pharmaceutical Market Europe
Published on 18 May 2023

Description:

Achieving better patient pathways with a focus on the patient; Why TB remains a major global public health challenge; The impact of rare diseases

Preview:

51 articles from this collection:
PME May 2023
PME May 2023
2 - 25 COMMUNIQUE AWARDS 23
2 - 25 COMMUNIQUE AWARDS 23
3 - Comment
3 - Comment
4 - PMLIVE PME
4 - PMLIVE PME
5 - Contents
5 - Contents
6-7 - News
6-7 - News
6-7 - PME - Pharma Market Europe Pharmaceutical News
8-9 - News
8-9 - News
10 - Coronavirus news
10 - Coronavirus news
11 - Dermatology news
11 - Dermatology news
12 - DARWIN'S MEDICINE - Adaptive innovation
12 - DARWIN'S MEDICINE - Adaptive innovation
12 - Pharma Market Europe Darwin’s medicine
13 - POLICY AND PUBLIC HEALTH - Generative AI is coming  for healthcare
13 - POLICY AND PUBLIC HEALTH - Generative AI is coming for healthcare
14 - MIKE DIXON - There’s always one more thing to learn
14 - MIKE DIXON - There’s always one more thing to learn
15 - INNOVATIVE IMPACT BLOG - THE OMNICHANNEL CONUNDRUM
15 - INNOVATIVE IMPACT BLOG - THE OMNICHANNEL CONUNDRUM
16-17 - TUBERCULOSIS - Using the power of data to future-proof the clinical development industry
16-17 - TUBERCULOSIS - Using the power of data to future-proof the clinical development industry
18 - TL ANTHEM - The need for a refreshingly different approach to achieving behaviour change
18 - TL ANTHEM - The need for a refreshingly different approach to achieving behaviour change
Supporting the most vulnerable:  why pharma should get behind the NHS’ healthcare equity campaign
Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
20-22 - RARE DISEASES - The 17th World Congress on Controversies in Neurology
20-22 - RARE DISEASES - The 17th World Congress on Controversies in Neurology
23 - FlyPharmaEurope
23 - FlyPharmaEurope
24-25 - PARKINSON’S DISEASE - Parkinson’s disease:  past, present and future
24-25 - PARKINSON’S DISEASE - Parkinson’s disease: past, present and future
26 - TL BEDROCK - Gene therapy, gene editing and perspectives on future use in Parkinson’s disease
26 - TL BEDROCK - Gene therapy, gene editing and perspectives on future use in Parkinson’s disease
27 - TRENDS: Creating communications excellence
27 - TRENDS: Creating communications excellence
28 - TRENDS: Langland
28 - TRENDS: Langland
28 - TRENDS: 67 Health
28 - TRENDS: 67 Health
29 - TRENDS: 90ten
29 - TRENDS: 90ten
29 - TRENDS: akt health
29 - TRENDS: akt health
30 - TRENDS: Anthem
30 - TRENDS: Anthem
30 - TRENDS: aurora
30 - TRENDS: aurora
31 - TRENDS: bcms
31 - TRENDS: bcms
31 - TRENDS: Bedrock
31 - TRENDS: Bedrock
32 - TRENDS: Edelman
32 - TRENDS: Edelman
32 - TRENDS: gci health
32 - TRENDS: gci health
33 - TRENDS: havas life medicom
33 - TRENDS: havas life medicom
33 - TRENDS: HCG Healhcare Consultancy Group
33 - TRENDS: HCG Healhcare Consultancy Group
34 - TRENDS: iNIZIO Medical
34 - TRENDS: iNIZIO Medical
34 - TRENDS: M+F Health
34 - TRENDS: M+F Health
35 - TRENDS: Madano
35 - TRENDS: Madano
35 - TRENDS: Makara
35 - TRENDS: Makara
36 - TRENDS: Page & Page and Partners
36 - TRENDS: Page & Page and Partners
36 - TRENDS: SAY Communications
36 - TRENDS: SAY Communications
37 - TRENDS: Sciterion
37 - TRENDS: Sciterion
37 - TRENDS: VIRGO Health
37 - TRENDS: VIRGO Health
38-40 - PATIENT PATHWAYS - Working together to achieve better patient pathways
38-40 - PATIENT PATHWAYS - Working together to achieve better patient pathways
41 - TL ORIGINS - Engaging with patients will create more effective patient pathways
41 - TL ORIGINS - Engaging with patients will create more effective patient pathways
42-44 - PATIENT PATHWAYS - Can the patient pathway provide a route to success?
42-44 - PATIENT PATHWAYS - Can the patient pathway provide a route to success?
44 - TL EVOKE - How an AI algorithm might save your life
44 - TL EVOKE - How an AI algorithm might save your life
RARE DISEASES - To support patient-centricity in clinical trials, look to rare disease communities
RARE DISEASES - To support patient-centricity in clinical trials, look to rare disease communities
46-48 - Appointments
46-48 - Appointments
49 -  HEALTHCARE COMMS
49 - HEALTHCARE COMMS
50 - ESPERION Q&A - Cardiovascular disease: the impact of COVID-19 on patient outcomes
50 - ESPERION Q&A - Cardiovascular disease: the impact of COVID-19 on patient outcomes
51 - PharmaRole
51 - PharmaRole
52 - PMPS SAMEDAN
52 - PMPS SAMEDAN